Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. The company develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic, and localized diseases, enabling physician...
EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. The company develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic, and localized diseases, enabling physicians to cure neurogenic bladder disorders post a spinal cord injury.

List your booth number for exhibitions, ask us